Search
Ocrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigationalIt was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. … In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a].
mRNA-1010
go.drugbank.com/drugs/DB22484Approved[L64058] The FDA approved mFLUSIVA on August 5, 2026 for active immunization against influenza in adults 50 years of age and older, making it the first mRNA-based influenza vaccine approved in the United … benefit to be confirmed in a postmarketing trial.
Sampatrilat
go.drugbank.com/drugs/DB21283ExperimentalSampatrilat has a monoisotopic molecular weight of 584.25 Da.
Categories: Agents Acting on the Renin-Angiotensin SystemIsoflavone
go.drugbank.com/drugs/DB12007ApprovedInvestigationalWithdrawnSoybean is an exceptionally rich source of dietary isoflavones, where the average isoflavone content is 1-2 mg/gram [A33103]. … Isoflavone is found as one of constituents in oral over-the-counter dietary supplements indicated for improved bone mass density and body fat regulation.
Iolopride I-123
go.drugbank.com/drugs/DB20028ExperimentalThe usage of the INN stem '-pride' in the name indicates that Iolopride I-123 is a sulpiride derivative and analogue. Iolopride I-123 has a monoisotopic molecular weight of 400.06 Da.
Categories: Compounds used in a research, industrial, or household settingPhenothrin
go.drugbank.com/drugs/DB13717InvestigationalMixtures: HERKLIN CLÁSICO-DUOCategories: Compounds used in a research, industrial, or household settingRibociclib
go.drugbank.com/drugs/DB11730ApprovedInvestigationalRibociclib was approved by the FDA in March 2017 under the brand name Kisqali.
Gadoquatrane
go.drugbank.com/drugs/DB33282Approvedin the central nervous system and in the body. … [L63930] Bayer announced FDA approval of gadoquatrane on June 15, 2026, for use with MRI in adult and pediatric patients, including term neonates, to detect and visualize lesions with abnormal vascularity
Zucapsaicin
go.drugbank.com/drugs/DB09120ApprovedWithdrawnZucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved.